[Basedow-Graves' disease: analysis of various parameters in the prognosis of remission after clinical treatment].
Fifty patients with Graves' disease were evaluated in relation to their outcome following medical treatment: goiter size, T3/T4 ratio, TSH and TSAb plasma levels were studied. Patients were followed for 8-20 months of medical treatment with PTU and 24-36 months thereafter. Thirty patients were eliminated for abandoning treatment (50%) or due to PTU side-effects (10%). The 20 patients remaining presented similar remission/relapse rates regardless of their T3/T4 ratio, greater than 20 (21% vs. 79%) or less than 20 (16% vs. 84%). Patients with TSH levels greater than 0.10 uU/ml immediately after PTU withdrawal presented a slight increase of remission rate (30% vs. 10%). Patients with goiter size greater than 60 cm3 at the beginning of medical treatment presented a remission rate of 8%, while those with goiters less than or equal to 60 cm3 showed a remission rate of 50%. Finally, normalization of TSAb levels (less than 15%) occurred at a remission rate of 100%, while all patients who did not achieve this goal relapsed shortly after PTU withdrawal. Based on these results, the authors conclude that the determination of TSAb levels is a reliable parameter of predict remission of Graves' disease following medical treatment.
Dias Júnior
A A
AA
Scalissi
N M
NM
Marone
M M
MM
Correa
P H
PH
Bianco
A C
AC
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011441:Propylthiouracil / Q000627:therapeutic use*; D011446:Prospective Studies; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D014284:Triiodothyronine; D011441:Propylthiouracil; D013972:Thyrotropin; D013974:Thyroxine
Doença de Basedow-Graves: análise de diferentes parâmetros na previsão de remissão após tratamento clínico.